The Spectranetics Corporation (NASDAQ:SPNC) Files An 8-K Regulation FD Disclosure

The Spectranetics Corporation (NASDAQ:SPNC) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure.

On January 24, 2017 The Spectranetics Corporation (the Company)
issued a press release regarding the final 12-month results of
the Stellarex Drug-coated Balloon (DCB) ILLUMENATE Global Study.
The results were presented at the Leipzig Interventional Course
(LINC) in Leipzig, Germany on January 24, 2017, by Professor
Thomas Zeller, University Heart Center Freiburg-Bad Krozingen,
Germany, global principal investigator for the ILLUMENATE Global
A copy of the press release is furnished as Exhibit 99.1 to this
Current Report. Additionally, a copy of Professor Zellers
presentation is furnished as Exhibit 99.2 to this Current Report.
The information contained in the press release and presentation
furnished herewith is preliminary and subject to change. The
press release and presentation also contain forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934
and the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are subject to risks and
uncertainties. For a list and description of such risks and
uncertainties that could cause actual results, performance or
achievements to materially differ from any anticipated results,
performance or achievements, please see the Companys previously
filed SEC reports, including those risks set forth in the press
release, in the Companys 2015 Annual Report on Form 10-K, and our
Quarterly Reports on Form 10-Q. The Company disclaims any
intention or obligation to update or revise any financial or
other projections or other forward-looking statements, whether
because of new information, future events or otherwise.
The information contained in this Current Report on Form 8-K,
including Exhibits 99.1 and 99.2, is being furnished and is not
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, and is not incorporated by reference into
any filing of The Spectranetics Corporation, whether made before
or after the date hereof, regardless of any general incorporation
language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Press release of The Spectranetics Corporation dated
January 24, 2017.
Professor Thomas Zeller, on behalf of Dr. Andrew
Holden, Professor Yann Goueffic and the ILLUMENATE
Global Investigators, ILLUMENATE Global Study Stellarex

About The Spectranetics Corporation (NASDAQ:SPNC)

The Spectranetics Corporation is a United States-based company, which develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are available in over 65 countries and are used to cross, prepare and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The Company’s segments include U.S. Medical and International Medical. The U.S. Medical segment offers medical devices, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment), and the service of the excimer laser system (service). The International Medical segment serves Europe, the Middle East, Asia Pacific, Latin America and Puerto Rico, and provides Stellarex DCB and AngioSculptX products, which are available for sale in Europe. The Company’s solutions include Lead Management, Peripheral Intervention and Coronary Intervention.

The Spectranetics Corporation (NASDAQ:SPNC) Recent Trading Information

The Spectranetics Corporation (NASDAQ:SPNC) closed its last trading session up +0.75 at 25.55 with 322,417 shares trading hands.

An ad to help with our costs